



5-13-02

1645-  
#3

Patent  
267/033

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: ) Group Art Unit: 1645  
RAMESHWAR, Pranela ) Examiner: not yet assigned  
Serial No.: 10/039,272 ) RECEIVED  
Filed: October 20, 2001 ) MAY 16 2002  
For: HEMATOPOIETIC GROWTH FACTOR ) TECH CENTER 1600/2900  
INDUCIBLE NEUROKININ-1 GENE )

TRANSMITTAL FOR INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231  
Sir:

I. DOCUMENTS ENCLOSED:

Applicant submits the following documents with this Transmittal Letter.

- (1) Information Disclosure Statement;
- (2) Form PTO-1449;
- (3) References AG to BN; and
- (4) Postcard.

---

LA-235769.1

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

---

May 7, 2002

---

Date of Deposit

Rachel Marquez

Name of Person Mailing Paper


Signature of Person Mailing Paper

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) or any fees required by this filing to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,  
LYON & LYON LLP

Dated: 5/7/02

By:

  
\_\_\_\_\_  
Sandra S. Fujiyama  
Reg. No. 46,713



**22249**

PATENT TRADEMARK OFFICE

LYON & LYON LLP  
633 W. Fifth Street, Suite 4700  
Los Angeles, CA 90071  
Phone: (213) 489-1600  
Fax: (213) 955-0440



Patent  
267/033

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: ) Group Art Unit: 1645  
RAMESHWAR, Pranela ) Examiner: not yet assigned  
Serial No.: 10/039,272 )  
Filed: October 20, 2001 )  
For: HEMATOPOIETIC GROWTH FACTOR )  
INDUCIBLE NEUROKININ-1 GENE )

RECEIVED  
MAY 16 2002  
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

LA-235569.1

CERTIFICATE OF MAILING  
(37 C.F.R. § 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

May 7, 2002  
Date of Deposit

Rachel Marquez

Name of Person Mailing Paper

Signature of Person Mailing Paper

**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) or any fees required by this filing to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,  
LYON & LYON LLP

Dated: 5/6/02

By: Sandra S. Fujiyama  
Sandra S. Fujiyama  
Reg. No. 46,713



**22249**

PATENT TRADEMARK OFFICE

LYON & LYON LLP  
633 W. Fifth Street, Suite 4700  
Los Angeles, CA 90071  
Phone: (213) 489-1600  
Fax: (213) 955-0440

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:  
SHAMESHWAR, PranelaFILING DATE:  
October 20, 2001

GROUP:



*RECEIVED*

*MAY 13 2002*

*TECH CENTER 1600/2900*

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	MAY CLASS J	SUB CLASS	FILING DATE
AA					2002	
AB					1600/2900	
AC						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
AD						
AE						
AF						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AG	Abrahams et al., "Cyclic AMP regulates the expression of neurokinin receptors by neonatal rat spinal neurons in culture," J. Neurochem., Vol. 73, No. 1, (1999) pp. 50-58
AH	Adamus et al., "Effect of the neuropeptide substance P on the rat bone marrow-derived osteogenic cells in vitro," J. Cell. Biochem., Vol. 81, (2001) pp. 499-506
AI	Bairoch et al., "The PROSITE database, its status in 1997," Nucleic Acid Res., Vol. 25, No. 1, (1997) pp. 217-221
AJ	Biggs et al., "A human Id-like helix-loop-helix protein expression during early development," Proc. Nat'l Acad. Sci. USA, Vol. 89, (1992) pp. 1512-1516
AK	Cooper et al., "Differential expression of Id genes in multipotent myeloid progenitor cells: Id-1 is induced by early- and late-acting cytokines while Id-2 is selectively induced by cytokines that drive terminal granulocytic differentiation," J. Cell. Biochem., Vol. 71, (1998) pp. 277-285
AL	Corpet et al., "The ProDom database of protein domain families," Nucleic Acid Res., Vol. 26, No. 1, (1998) pp. 323-326
AM	Gerard et al., "Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones," Biochemistry, Vol. 30, (1991) pp. 10640-10646
AN	Hegde et al., "c-Maf induces monocytic differentiation and apoptosis in bipotent myeloid progenitors," Blood, Vol. 94, No. 5, (9/1/1999) pp. 1578-1589
AO	Ho et al., "Human monocytes and macrophages express substance P and neurokinin-1 receptor," J Immunol., Vol. 159, (1997) pp. 5654-5660
AP	International Polycystic Kidney Disease Consortium, The, "Polycystic kidney disease: The complete structure of the PKD1 gene and its protein," Cell, Vol. 81, (1995) pp. 289-298
AQ	Ishiguro et al., "Id2 expression increases with differentiation of human myeloid cells," Blood, Vol. 87, No. 12, (1996) pp. 5225-5231
AR	Krause et al., "Structure, functions, and mechanisms of substance P receptor action," J. Invest. Dermatol., Vol. 98, No. 6, (6/1992) pp. 2S-7S

LA-229272.1


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

## LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
266/033SERIAL NO.  
10/039,272APPLICANT:  
JAMESHWAR, PranelaFILING DATE:  
October 20, 2001

GROUP:

**RECEIVED**

	AS	Maggi, "Tachykinins in the autonomic nervous system," <i>Pharmacol. Res.</i> , Vol. 33, No. 3, (1996) pp. 161-170
	AT	Marriott et al., "IL-4 and IFN-γ up-regulate substance P receptor expression in murine peritoneal macrophages," <i>J. Immunol.</i> , Vol. 165, No. 1, (2000) pp. 182-191
	AU	Massari et al., "Helix-Loop-Helix proteins: Regulators of transcription in eucaryotic organisms," <i>Mol. Cell. Biol.</i> , Vol. 20, No. 2, (1/2000) pp. 429-440
	AV	Miura et al., "Pyk2 and Syk participate in functional activation of granulocytic HL-60 cells in a different manner," <i>Blood</i> , Vol. 96, No. 5, (9/1/2000) pp. 1733-1739
	AW	Muller-Sieburg et al., "The stromal cells' guide to the stem cell universe," <i>Stem Cells</i> , Vol. 13, (1995) pp. 477-486
	AX	Norton et al., "Id helix-loop-helix proteins in cell growth and differentiation," <i>Trends Cell Biol.</i> , Vol. 8, (2/1998) pp. 58-65
	AY	Quinn et al., "Molecular models to analyse preprotachykinin-A expression and function," <i>Neuropeptides</i> , Vol. 34, No. 5, (2000) pp. 292-302
	AZ	Rameshwar, "Substance P: A regulatory neuropeptide for hematopoiesis and immune functions," <i>Clin. Immunol. Immunopath.</i> , Vol. 85, No. 2, (2000) pp. 129-133
	BA	Rameshwar et al., "Hematopoietic regulation mediated by interactions among the neurokinins and cytokines," <i>Leuk. Lymphoma</i> , Vol. 28, (1997) pp. 1-10
	BB	Rameshwar et al., "Receptor induction regulates the synergistic effects of substance P with IL-1 and PDGF on the proliferation of bone marrow fibroblasts," <i>J. Immunol.</i> , Vol. 158, (1997) pp. 3417-3424.
	BC	Rameshwar et al., "Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P-immunoreactivity in patients with bone marrow fibrosis," <i>Blood</i> , Vol. 97, No. 10, (5/15/2001) pp. 3025-3031.
	BD	Rameshwar et al., "NF-κB as a central mediator in the induction of TGF-β in monocytes from patients with idiopathic myelofibrosis: An inflammatory response beyond the realm of homeostasis," <i>J. Immunol.</i> , Vol. 165, (2000) pp. 2271-2277
	BE	Randall, "Characterization of a population of cells in the bone marrow that phenotypically mimics hematopoietic stem cells: resting stem cells or mystery population?" <i>Stem Cells</i> , Vol. 16, (1998) pp. 38-48
	BF	Roodman, "Cell biology of the osteoclast," <i>Exp. Hematol.</i> , Vol. 27, (1999) pp. 1229-1241
	BG	Rost et al., "Combining evolutionary information and neural networks to predict protein secondary structure," <i>Proteins</i> , Vol. 19, (1994) pp. 55-72
	BH	Rost et al., "Prediction of protein structure at better than 70% accuracy," <i>J. Mol. Biol.</i> , Vol. 232, (1993) pp. 584-599
	BI	Rupniak, "Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor (NK <sub>1</sub> ) antagonists," <i>Tachykinins 2000</i> , (2000) p. 2a
	BJ	Singh et al., "Increased expression of preprotachykinin-1 and neurokinin receptors in human breast cancer cells. Implications for bone marrow metastasis," <i>Proc. Nat'l Acad. Sci. USA</i> , Vol. 97, No. 1, (1/4/2000) pp. 388-393
	BK	Sonhammer, E.L., G. Heijne, and A. Krogh. 1998. A hidden Markov model for predicting transmembrane helices in protein sequences. pp.175-182. In Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen (ed.), <i>Proceedings of 6<sup>th</sup> International Conference on Intelligent Systems for Molecular Biology</i> . Menlo Park, CA.
	BL	Tabarowski et al., "Noradrenergic and peptidergic innervation of the mouse femur bone marrow," <i>Acta Histochem.</i> , Vol. 98, (1996) pp. 453-457
	BM	Weterman et al., "nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts," <i>Int. J. Cancer</i> , Vol. 60, (1995) pp. 73-81
	BN	Yao et al., "Neurokinin-1 expression and colocalization with glutamate and GABA in the hypothalamus of the cat," <i>Mol. Brain Res.</i> , Vol. 71, (1999) pp. 149-158

LA-229272.1

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	